MIRA submits Phase 2a protocol to FDA for Ketamir-2 in chemotherapy-induced neuropathy

Mira Pharmaceuticals announced submission of a Phase 2a clinical trial protocol for Ketamir-2, an oral NMDA receptor modulator, to treat chemotherapy-induced peripheral neuropathy (CIPN), which affects millions of cancer patients annually with no approved therapies. The randomized, double-blind, placebo-controlled study addresses a significant unmet medical need in oncology supportive care where current treatments remain incomplete.